62%
Max LDL-C Drop
from one infusion, highest dose · Heart-2 Phase 1b interim, May 2026
88%
Max PCSK9 Knockdown
the gene it switches off · durable to 18 months so far
~35
Humans Dosed
Phase 1b only · no Phase 3, no outcome data, no approval
0
FDA-Approved Uses
investigational; Fast Track granted; Phase 2 to begin late 2026
Statins, the PCSK9 shots, and inclisiran all lower LDL by roughly half — but only while you keep taking them, and all four bars for those drugs come from independent, peer-reviewed, placebo-controlled trials with thousands of patients. VERVE-102's pitch is different: edit the gene once and the lowering is meant to stay without any more doses. Its bar looks tallest — but it is the only bar on this chart drawn from a drugmaker's own press release in ~35 people, not from a published, independently reviewed trial. Read the height as "what the sponsor is claiming so far," not as an apples-to-apples win. (LDL-lowering figures: VERVE-102 from the company Heart-2 readout, not yet peer-reviewed; statin/inclisiran/mAb from peer-reviewed PubMed sources — see footer.)
High-Intensity Statin
Pill, every day, forever. ~50% LDL drop. Decades of outcome proof.
Inclisiran (Leqvio)
siRNA shot, 2×/year, forever. ~50% (ORION-10/11).
PCSK9 Antibody
Self-injection q2–4 wks, forever. ~50–60% (Repatha/Praluent).
VERVE-102 (1 dose)
Single IV infusion. Up to 62% per the sponsor's own release — only ~35 people, no independent replication, no outcome data yet.
This isn't a drug that blocks a protein — it's a one-time instruction that turns a gene off at the source. The therapy uses an adenine base editor (a CRISPR cousin that swaps a single DNA base, A→G, without cutting the strand) carried to liver cells inside a fatty bubble (a lipid nanoparticle). It flips one letter in the PCSK9 gene so the liver stops making that protein — which means more LDL receptors stay on liver cells, pulling more LDL out of the blood. The genetics behind why that lowers heart attacks were settled 20 years ago (next section).
The Edit
A → G
An adenine base editor changes a single DNA base in PCSK9 to install a "stop" — permanently silencing the gene in treated liver cells. No double-strand cut, which is meant to be safer than classic CRISPR.
The Delivery
LNP → Liver
A lipid nanoparticle carries the editor's mRNA + guide to the liver via the bloodstream. VERVE-102's redesigned LNP adds GalNAc — a sugar tag that docks onto liver cells specifically.
The Target: PCSK9
Brake-Release
PCSK9 normally destroys LDL receptors, so LDL stays high. Switch PCSK9 off and the receptors survive longer — the liver clears more LDL. This is exactly how the existing PCSK9 drugs work, but done once at the gene.
Why "One-Time"
Permanent
A DNA edit is copied when liver cells divide, so the effect is meant to last for life from a single dose — vs. statins (daily), antibodies (every 2–4 weeks), or inclisiran (twice a year), all forever.
VERVE-102 isn't a hunch. Some people are born with a broken PCSK9 gene — a natural "loss-of-function" mutation — and have had low LDL their whole lives with no apparent harm. In 2006, Cohen & Hobbs showed these people get far fewer heart attacks. That 20-year-old discovery is the entire rationale: VERVE-102 tries to copy, on purpose, what a lucky few inherited by accident. (According to PubMed.)
2003
PCSK9 discovered as a cholesterol gene
Gain-of-function mutations cause severe inherited high cholesterol; loss-of-function does the opposite.
2006
Born without it → 88% fewer heart events
Nonsense PCSK9 mutations: 28% lower LDL →
88% lower coronary heart disease risk (Black cohort); 15% LDL / 47% lower in white cohort.
PMID 16554528
2015–21
Two PCSK9 drugs prove the target in people
Antibodies (evolocumab, alirocumab) then inclisiran cut LDL ~50% and reduce events — confirming "lower PCSK9 = lower risk."
PMID 37331523
2022
Gene edit works in monkeys, lasts 476 days
VERVE-101 in primates: 83% PCSK9 & 69% LDL drop, durable >15 months, no germline (heritable) editing detected.
PMID 36314243
2025–26
VERVE-102 reaches humans (newest data)
Heart-2 Phase 1b: up to 62% LDL / 88% PCSK9 from one dose, durable to 18 mo. Still ~35 people, no heart-attack-prevention data yet.
There is no peer-reviewed journal paper on VERVE-102's human results yet — the data exists as company press readouts and conference presentations, corroborated by independent medical press (tctmd, HCPLive). That's an honest evidence tier: real registered-trial data, but not yet through journal peer review. The whole program is Phase 1b. Here's the chain, including the VERVE-101 trial whose safety pause forced the redesign.
| # |
Trial / Readout |
Stage / n |
What It Showed |
| 1 |
Heart-2 — VERVE-102, newest interim (Lilly/Verve, May 2026)
|
Phase 1b
~35 dosed |
Up to 62% LDL
PCSK9 down up to 88% (51–88% range); LDL-C down up to 62% at 1.0 mg/kg; dose-dependent; durable to 18 months. No treatment-related serious AEs, no dose-limiting toxicities. |
| 2 |
Heart-2 — VERVE-102, first efficacy readout (Mar 2025 cutoff)
|
Phase 1b
n=14 |
53% mean LDL
At 0.6 mg/kg: mean 53%, max 69% LDL-C drop. No clinically significant ALT/AST, bilirubin or platelet changes; one grade-2 infusion reaction (resolved). |
| 3 |
Heart-1 — VERVE-101 (prior molecule, enrollment paused Apr 2024)
|
Phase 1b
paused |
Safety pause
Proved the concept (dose-dependent LDL/PCSK9 lowering) but one patient had grade-3 transient liver-enzyme rise + low platelets at 0.45 mg/kg, plus infusion reactions — attributed to the LNP. Verve moved to VERVE-102's redesigned delivery. |
| 4 |
Primate & mouse preclinical (VERVE-101 surrogate)
|
Animal
n=26 NHP |
69% LDL, durable
83% PCSK9 & 69% LDL drop at 1.5 mg/kg, durable to 476 days; transient liver-enzyme rise resolved by day 14; 0/436 mouse offspring inherited the edit. |
VERVE-102 has no official price — it isn't for sale and won't be for years. But the whole economic argument for a one-time edit is "pay once instead of forever," so here's what "forever" actually costs today in the US, plus an honest read on what "once" is realistically expected to cost. A generic statin is the cheap, proven workhorse; the gene edit is the unpriced, unproven moonshot at the other end — and gene therapies to date have priced far above any drug on this chart.
Most Proof, Cheapest
Generic Statin
$48–240
per year, cash
Daily pill, forever · ~50% LDL · decades of heart-outcome proof
Ezetimibe (generic)
$180–480
per year, cash
Daily pill, forever · add-on, ~15–20% extra LDL drop
PCSK9 Antibody (Repatha / Praluent)
~$5,850–6,200
per year, list (WAC)
Self-inject q2–4 wks, forever · ~50–60% LDL
Inclisiran (Leqvio)
~$6,500
per year, list (WAC)
2 office shots/year, forever · ~50% LDL (ORION-10/11)
Investigational
VERVE-102 (gene edit)
No price
not for sale — trial only
One IV infusion, in theory for life · up to 62% LDL in ~35 people
If Approved — Realistic Estimate
Every FDA-approved gene/base-editing therapy so far
$2.1M–$3.5M
one-time list price, today's market
Zolgensma $2.1M · Casgevy $2.2M · Hemgenix $3.5M · analysts think VERVE-102 could land far lower (~$100K–200K) given its larger patient pool and cheap manufacturing — but that's a projection, not a set price, and Lilly sets the number, not the reader
The single most important thing to understand: VERVE-102 is not approved by anyone, for anything. It can only be received inside a clinical trial. Here is the actual status as of mid-2026.
FDA
Investigational — Fast Track only
Not approved. The FDA granted Fast Track designation (a process to speed review of serious-disease drugs) — that is NOT approval and not a verdict on whether it works. It remains a clinical-trial-stage experimental product.
Development Stage
Phase 1b → Phase 2 (late 2026)
Still in the smallest, earliest human stage (Phase 1b). Lilly plans to start Phase 2 enrollment by the end of 2026. A pivotal Phase 3 outcomes trial — the kind that could support approval — has no public start date.
Ownership / Backing
Acquired by Eli Lilly (~$1.3B)
Lilly agreed to buy Verve Therapeutics in June 2025 for $10.50/share plus a $3.00 milestone payment tied to dosing the first US Phase 3 patient — ~$1.3B total. A big-pharma backer means deep pockets to fund the trials, not a shortcut to approval.
Who Profits & Who Talks
Every human efficacy number on this page is sponsor-released
The 62% LDL / 88% PCSK9 figures come from Lilly and Verve's own press releases, not an independent trial report. Verve's co-founder/CEO holds roughly $8–12M in company stock that vested on the Lilly deal and told investors manufacturing costs are "very manageable" — a claim from the person with the biggest incentive to make this sound cheap and safe. That doesn't make the data false; it means every number needs the "who said so" label attached, which independent replication hasn't happened yet to confirm.
A permanent DNA edit is a one-way door — that's both the appeal and the risk. The early safety data look clean so far, but "so far" means ~35 people and ~18 months. Here is what is genuinely not yet known.
It's Permanent — No Undo
Unlike a pill you can stop, a base edit can't be reversed. If a long-term problem emerged years later, you couldn't switch it back off. For a young patient, "for life" also means decades of follow-up nobody has yet.
The VERVE-101 Warning
The prior molecule's trial was
paused after a patient had a grade-3 liver-enzyme spike and low platelets, blamed on the delivery particle. VERVE-102 was redesigned to fix that and looks cleaner — but it's the reason caution is warranted.
BioPharma Dive
Off-Target Edits
Base editors can, in principle, change DNA at unintended spots. Preclinical work screened for this and the design avoids strand cuts, but lifelong off-target risk in humans can only be answered by long, large trials — not yet done.
PMID 37259866
No Outcome Proof
Every number so far is LDL and PCSK9 — lab markers. Lowering LDL should cut heart attacks (the genetics say so), but VERVE-102 itself has not been shown to prevent a single cardiac event. That requires a Phase 3 outcomes trial that hasn't started.
All Data Is Company-Reported, No Outside Review Yet
Every VERVE-102 human number circulating — 62% LDL, 88% PCSK9, "no dose-limiting toxicities" — comes from Lilly/Verve press releases and conference slides, selected and worded by the sponsor. No independent lab has replicated it and no peer-reviewed paper on the human results exists yet. Independent physicians reviewing the data have flagged the infusion reactions as "more significant" than with the existing PCSK9 drugs, and note patients needed steroid/antihistamine pre-medication that the older drugs don't require.
tctmd, independent cardiology press
Bottom-line risk framing: The reassuring part — people born with a broken PCSK9 gene are healthy with low LDL, and no germline (heritable) editing was seen in animals. The part that's still entirely unproven — doing it deliberately, in a liver, with a delivery particle, on sponsor-reported data in ~35 people, and trusting it for 40+ years with no undo button — is something only independent, peer-reviewed, large, long trials can validate, and none of that exists yet. Nobody should treat this as available, settled, or proven safe long-term.
The Bottom Line — In Plain English
VERVE-102 is an experimental, one-time gene-editing infusion, owned by Eli Lilly, that switches off the liver's PCSK9 gene to lower LDL cholesterol — aiming to do in a single dose what statins and PCSK9 drugs do only as long as you keep taking them. The newest human numbers are the sponsor's own, drawn from ~35 people with no independent replication and no peer review yet — a real early signal, not a proven result. It is also permanent and irreversible, which is the trade-off no marketing deck leads with.
What It Is
A CRISPR-cousin "base editor" delivered to the liver that permanently turns off PCSK9, so the body clears more LDL from the blood. One IV infusion, meant to last for life.
What The Newest Data Show
In Heart-2 (May 2026), Lilly/Verve's own release says a single dose cut PCSK9 up to 88% and LDL up to 62%, holding for up to 18 months — in only ~35 people, self-reported by the sponsor, not yet independently verified or peer-reviewed, and with no proof it prevents heart attacks.
How It Compares
Statins (~$48–240/yr, daily, decades of independent outcome proof), PCSK9 shots and inclisiran (~$6,000/yr, forever, ~50% LDL, published RCTs) all lower LDL repeatedly, cheaply, and with a known track record. VERVE-102's only edge is "once" — and that's unproven and will likely cost far more per dose than years of the alternatives combined.
Its Status
Investigational. NOT FDA-approved, NOT for sale, available only in a trial, likely a decade or more from any approval decision. Phase 1b now; Phase 2 starting late 2026; owned by Eli Lilly after a ~$1.3B deal that pays Verve's founders and investors on trial milestones, not on the drug actually working.
Honest Verdict
A genetically well-grounded idea with a real, if small and sponsor-reported, early signal — wrapped in the kind of press-release science that mature drugs don't need. It is permanent, unproven on outcomes, has no independent safety record beyond ~35 people, and will likely be priced far above what most people can pay out of pocket. Interesting to watch; nothing here supports betting your cholesterol strategy on it, and nothing here should make a $50/year statin sound like the lesser option.
The genetics behind the idea are solid. People born with a naturally broken PCSK9 gene have had low LDL and fewer heart attacks their whole lives (Cohen & Hobbs, NEJM 2006) — that part is independent, peer-reviewed, 20-year-old science. VERVE-102 tries to recreate that on purpose, but the leap from "the target is validated" to "this specific product is safe and effective" has not been made by anyone outside the company that owns it. (Genetics and mechanism per PubMed; human VERVE-102 results from company readouts corroborated by independent medical press, not yet by a peer-reviewed paper.)
- One-time concept: edit once, lower LDL for life — vs. a lifetime of daily pills or repeat injections, IF it works and stays safe long-term
- Newest readout (Heart-2, May 2026): up to 88% PCSK9 and up to 62% LDL drop from a single infusion — self-reported by Lilly/Verve, not independently confirmed
- Still Phase 1b: ~35 people, ~18-month follow-up, no peer-reviewed paper, and no heart-attack-prevention data
- The prior molecule (VERVE-101) was paused for a liver/platelet safety signal; independent reviewers flag VERVE-102's infusion reactions as more significant than existing PCSK9 drugs
- A base edit is permanent and can't be undone — there is no way to reverse a problem that shows up years later
- Not approved, not available, no set price; every approved gene therapy to date has cost $2M–$3.5M, and Lilly — not the patient — will set the number